Precision BioSciences, Inc. (DTIL) Stock

Precision BioSciences, Inc. (DTIL) is a Healthcare stock trading at $6.79 (as of 2026-06-18), with a market capitalization of $179.84M and a trailing P/E of -3.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Precision BioSciences, Inc. develops in vivo gene editing and ex vivo allogeneic CAR T immunotherapies, including a genome-editing platform and multiple investigational CAR T candidates. Its pipeline includes programs such as PBCAR0191 and PBCAR19B for hematologic malignancies and PBCAR269A for multiple myeloma, with development activities conducted under collaboration agreements with other entities.

Valuation — source: SEC EDGAR (first-party)
Price	$6.79
Market Cap	$179.84M
P/E Ratio	-3.1
EV / EBITDA	-1.1
Price / Book	2.20
Price / Sales	3.72
DCF Value (model)	$-39.84
DCF Upside vs Price	-687.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$34.26M
Net Margin	-133.4%
Return on Equity	-57.3%
Current Ratio	14.02
Revenue Growth (YoY)	-50.1%
EPS Growth (YoY)	-439.0%
FCF Growth (YoY)	12.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-3.21 (distress)

Valuation vs Sector & Industry
Stock P/E	-3.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-114.8%
vs Industry	-118.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Octagon Capital Advisors LP ($12.30M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Michael Amoroso
Employees	108
Country	US
IPO Date	2019-03-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.